Over 98% of all drugs struggle to cross the Blood-Brain Barrier (BBB), hindering their usability against CNS diseases. D2B3 is a patented human monoclonal antibody (Mab), that transiently and highly specifically opens the BBB, achieving high drug penetration to the brain. 
The lead asset D2B3 has shown exceptional performance in in vivo proof of concept studies delivering a variety of drug classes (small molecules to biologics) across the BBB and unlocking therapeutic efficacy in different rodent CNS-disease models. Expanding the reach of generic - off-patent - therapeutic assets to the brain, promises lowered regulatory burdens and fast clinical progression, bringing hope to patients living with CNS-diseases.